| |
|
|
|
|
|
 |
| |
|
±â°¡ÈǺóÅ©¸² GIGAFULVIN CREAM[Crotamiton , Dipotassium glycyrrhizinate , Lidocaine , Miconazole nitrate]
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
643600270
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
´ã¹é»öÀÇ Å©¸²Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 15±×·¥ |
1 °³ |
Æ©ºê |
8806436002708 |
8806436002715 |
|
|
| ÁÖ¼ººÐÄÚµå |
343900CCM
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
Á·ºÎ¹é¼±(¹«Á»), °íºÎ¹é¼±(¿Ï¼±), ¼Ò¼öÆ÷¼º ¹Ý»ó¹é¼±
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:343900CCM ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
1ÀÏ 1ȸ, ȯºÎ¿¡ Àû´ç·®À» µµÆ÷ÇÑ´Ù.
[Á¦Çüº°º¹¾àÁöµµ]
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ±Ý±â |
- ´«À̳ª ´«ÁÖÀ§, Á¡¸·(¿¹:
±¸°, ºñ°, Áú µî),À½³¶, ¿ÜÀ½ºÎ
½ÀÁø, À½ºÎÀÇ ½ÀÁø |
| ½ÅÁßÅõ¿© |
- ¾àÀ̳ª ÈÀåǰ µî¿¡ ÀÇÇÑ ¾Ë·¹¸£±â Áõ»ó(¿¹:
¹ßÁø, ¹ßÀû, °¡·Á¿ò, ÇǺκ´ µî)ÀÌ ³ªÅ¸³ ÀûÀÌ Àִ ȯÀÚ
ȯºÎ°¡ ¾È¸éÀ̰ųª ±¤¹üÀ§ÇÑ È¯ÀÚ
½ÀÀ±À̳ª Áø¹«¸§ÀÌ ½ÉÇÑ È¯ÀÚ
À¯,À¯¾Æ
ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ
ÀÌ ¾àÀº ÇÁ·ÎÇÊ·»±Û¸®ÄÝÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. |
| ÀÌ»ó¹ÝÀÀ |
ÀÌ ¾àÀÇ »ç¿ë¿¡ ÀÇÇØ ÇǺκ´, Àڱذ¨, ¹ßÁø ¹ßÀû, Áø¹«¸§, °¡·Á¿ò, °ÇÁ¶,´ç±â´Â ´À³¦, ³«¼³ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì »ç¿ëÀ» ÁßÁöÇϰí Àǻ糪 ¾à»ç¿Í »óÀÇÇÑ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| Á¦Çüº° º¹¾àÁöµµ |
[Å©¸²] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Lidocaine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Potassium¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Crotamiton¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching.
Lidocaine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.
Miconazole¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Miconazole interacts with 14-¥á demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Miconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.
|
| Pharmacology |
Crotamiton¿¡ ´ëÇÑ Pharmacology Á¤º¸ Crotamiton is usually used to treat pruritis (itching of the skin) caused by scabies or sunburn. Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Due to this cooling effect it is also effective for the relief of sunburn. The drug is also believed to kill scabies through an unknown mechanism.
Lidocaine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Lidocaine is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidocaine appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidocaine in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide.
Miconazole¿¡ ´ëÇÑ Pharmacology Á¤º¸ Miconazole is an anti-fungal medication related to fluconazole (Diflucan), ketoconazole (Nizoral), itraconazole (Sporanox), and clotrimazole (Lotrimin, Mycelex). It is used either on the skin or in the vagina for fungal infections. Miconazole was approved by the FDA in 1974. Miconazole prevents fungal organisms from producing vital substances required for growth and function. This medication is effective only for infections caused by fungal organisms. It will not work for bacterial or viral infections.
|
| Metabolism |
Crotamiton¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
Lidocaine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2D6 (CYP2D6)
Miconazole¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2C9 (CYP2C9)Cytochrome P450 2D6 (CYP2D6)
|
| Protein Binding |
Crotamiton¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
Lidocaine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 60-80%
Miconazole¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Crotamiton¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
Lidocaine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 109 minutes
Miconazole¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Crotamiton¿¡ ´ëÇÑ Absorption Á¤º¸ 10 % absorbed when applied locally.
Lidocaine¿¡ ´ëÇÑ Absorption Á¤º¸ Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent.
Miconazole¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
LidocaineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú¹ßÇö½Ã°£ (1ȸ bolus ¿ë·®À¸·Î¼) : 45-90ÃÊ
- ÀÛ¿ëÁö¼Ó½Ã°£ : 10-25ºÐ
- ºÐÆ÷ (Vd) : ¸¹Àº ¿äÀο¡ µû¶ó º¯ÈµÇ¸ç, ¿ïÇ÷¼º ½ÉºÎÀü°ú °£Áúȯ¿¡¼´Â ºÐÆ÷¿ëÀûÀÌ °¨¼ÒµÊ
- ´Ü¹é°áÇÕ : 60-80%, ¥á1-acid glycoprotein°ú °áÇÕ
- ´ë»ç : °£¿¡¼ 90% ´ë»ç
- Ȱ¼ºÇü ´ë»çüÀÎ monoethylglycinexylidide(MEGX)¿Í glycinexylidide(GX)°¡ ÃàÀûµÇ¾î ÁßÃ߽Űæ°è µ¶¼ºÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù.
- ¹Ý°¨±â (biphasic) : ¿ïÇ÷¼º ½ÉºÎÀü, °£Áúȯ, ¼îÅ©, ÁßÁõÀÇ ½ÅÁúȯ¿¡¼ Áõ°¡
- Ãʱâ : 7-30ºÐ
- ¸»±â : ¿µ¾Æ, ¹Ì¼÷¾Æ : 3.2½Ã°£, ¼ºÀÎ : 1.5-2½Ã°£
Miconazole nitrateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´Ü¹é°áÇÕ : 91-93%
- ´ë»ç : °£´ë»ç
- ¹Ý°¨±â : Multiphasic
- Ãʱâ : 40ºÐ
- Secondary : 126ºÐ
- Terminal : 24½Ã°£
- ¼Ò½Ç : 50%±îÁö º¯¹è¼³, 1% ¹Ì¸¸ÀÌ ¹Ìº¯Èü·Î ½Å¹è¼³
|
| Biotransformation |
Crotamiton¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
Lidocaine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Primarily hepatic.
Miconazole¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Crotamiton¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
Lidocaine¿¡ ´ëÇÑ Toxicity Á¤º¸ The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
Miconazole¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, mouse: LD50 = 3800 mg/kg; Oral, rat: LD50 = 3 gm/kg. Ingestion of the amounts of the components contained in a tube of cream are unlikely to produce overdosage and toxic effects.
|
| Drug Interactions |
Crotamiton¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acetohexamide The beta-blocker decreases the symptoms of hypoglycemiaChlorpropamide The beta-blocker decreases the symptoms of hypoglycemiaCimetidine Cimetidine increases the effect of the beta-blockerClonidine Increased hypertension when clonidine stoppedDisopyramide The beta-blocker increases toxicity of disopyramideGliclazide The beta-blocker decreases the symptoms of hypoglycemiaGlipizide The beta-blocker decreases the symptoms of hypoglycemiaGlisoxepide The beta-blocker decreases the symptoms of hypoglycemiaGlibenclamide The beta-blocker decreases the symptoms of hypoglycemiaGlycodiazine The beta-blocker decreases the symptoms of hypoglycemiaInsulin The beta-blocker decreases the symptoms of hypoglycemiaLidocaine The beta-blocker increases the effect and toxicity of lidocainePropafenone Propafenone increases the effect of beta-blockerRepaglinide The beta-blocker decreases the symptoms of hypoglycemiaRifampin Rifampin decreases the effect of the metabolized beta-blockerTelithromycin Telithromycin may possibly increase metoprolol effectTolazamide The beta-blocker decreases the symptoms of hypoglycemiaTolbutamide The beta-blocker decreases the symptoms of hypoglycemiaAmobarbital The barbiturate decreases the effect of metabolized beta-blockerAprobarbital The barbiturate decreases the effect of metabolized beta-blockerButalbital The barbiturate decreases the effect of metabolized beta-blockerButabarbital The barbiturate decreases the effect of metabolized beta-blockerButethal The barbiturate decreases the effect of metabolized beta-blockerDihydroquinidine barbiturate The barbiturate decreases the effect of metabolized beta-blockerHeptabarbital The barbiturate decreases the effect of metabolized beta-blockerHexobarbital The barbiturate decreases the effect of metabolized beta-blockerMethohexital The barbiturate decreases the effect of metabolized beta-blockerMethylphenobarbital The barbiturate decreases the effect of metabolized beta-blockerPentobarbital The barbiturate decreases the effect of metabolized beta-blockerPhenobarbital The barbiturate decreases the effect of metabolized beta-blockerPrimidone The barbiturate decreases the effect of metabolized beta-blockerQuinidine barbiturate The barbiturate decreases the effect of metabolized beta-blockerSecobarbital The barbiturate decreases the effect of metabolized beta-blockerTalbutal The barbiturate decreases the effect of metabolized beta-blockerCitalopram The SSRI increases the effect of the beta-blockerEscitalopram The SSRI increases the effect of the beta-blockerFluoxetine The SSRI increases the effect of the beta-blockerSertraline The SSRI increases the effect of the beta-blockerParoxetine The SSRI increases the effect of the beta-blockerDihydroergotamine Ischemia with risk of gangreneDihydroergotoxine Ischemia with risk of gangreneErgonovine Ischemia with risk of gangreneErgotamine Ischemia with risk of gangreneMethysergide Ischemia with risk of gangreneVerapamil Increased effect of both drugsHydralazine Increased effect of both drugsDiltiazem Increased risk of bradycardiaEpinephrine Hypertension, then bradycardiaFenoterol AntagonismFormoterol AntagonismIsoproterenol AntagonismOrciprenaline AntagonismPirbuterol AntagonismPrazosin Risk of hypotension at the beginning of therapyProcaterol AntagonismSalbutamol AntagonismSalmeterol AntagonismTerbutaline AntagonismIbuprofen Risk of inhibition of renal prostaglandinsIndomethacin Risk of inhibition of renal prostaglandinsPiroxicam Risk of inhibition of renal prostaglandins
Lidocaine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
Miconazole¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Warfarin Vaginal miconazole increases the anticoagulant effectAcenocoumarol Vaginal miconazole increases the anticoagulant effectDicumarol Vaginal miconazole increases the anticoagulant effectAnisindione Vaginal miconazole increases the anticoagulant effect
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Crotamiton¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
Lidocaine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
Miconazole¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Crotamiton¿¡ ´ëÇÑ Description Á¤º¸ Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.
Lidocaine¿¡ ´ëÇÑ Description Á¤º¸ A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem]
Miconazole¿¡ ´ëÇÑ Description Á¤º¸ An imidazole antifungal agent that is used topically and by intravenous infusion. [PubChem]
|
| Dosage Form |
Crotamiton¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream Topical
Lidocaine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol TopicalAerosol, metered TopicalCream TopicalGel TopicalJelly TopicalJelly UrethralLiquid BuccalLiquid DentalLiquid InfiltrationLiquid IntravenousLiquid OralLiquid TopicalLotion TopicalOintment TopicalSolution InfiltrationSolution IntramuscularSolution IntravenousSolution OralSolution TopicalSpray TopicalSwab Topical
Miconazole¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol TopicalCream IntravaginalCream TopicalSuppository Intravaginal
|
| Drug Category |
Crotamiton¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antiparasitic AgentsAntipruriticsPesticidesScabicides
Lidocaine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnestheticsAnesthetics, LocalAnti-Arrhythmia AgentsAntiarrhythmic Agents
Miconazole¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antifungal Agents
|
| Smiles String Canonical |
Crotamiton¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(C(=O)C=CC)C1=CC=CC=C1C
Lidocaine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
Miconazole¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
|
| Smiles String Isomeric |
Crotamiton¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(C(=O)\C=C\C)C1=CC=CC=C1C
Lidocaine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
Miconazole¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ ClC1=CC(Cl)=C(CO[C@@H](CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
|
| InChI Identifier |
Crotamiton¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C13H17NO/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10H,5H2,1-3H3
Lidocaine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)/f/h15H
Miconazole¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2
|
| Chemical IUPAC Name |
Crotamiton¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N-ethyl-N-(2-methylphenyl)but-2-enamide
Lidocaine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-diethylamino-N-(2,6-dimethylphenyl)acetamide
Miconazole¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
|
| Drug-Induced Toxicity Related Proteins |
DOCA ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Aquaporin-2 Drug:DOCA Toxicity:hypertension. [¹Ù·Î°¡±â] LIDOCAINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:glucose-regulated protein Drug:lidocaine Toxicity:intestinal disorder. [¹Ù·Î°¡±â] Replated Protein:Alkaline phosphatase Drug:lidocaine Toxicity:lidocaine induced hepatitis. [¹Ù·Î°¡±â] Replated Protein:C-reactive protein Drug:lidocaine Toxicity:fever. [¹Ù·Î°¡±â] Replated Protein:C-reactive protein Drug:lidocaine Toxicity:lidocaine induced hepatitis. [¹Ù·Î°¡±â] Replated Protein:Alpha-1-acid glycoprotein Drug:lidocaine Toxicity:lidocaine tolerance. [¹Ù·Î°¡±â] Replated Protein:Gamma-glutamyltranspeptidase Drug:lidocaine Toxicity:fever. [¹Ù·Î°¡±â] Replated Protein:Alkaline phosphatase Drug:lidocaine Toxicity:fever. [¹Ù·Î°¡±â] Replated Protein:Gamma-glutamyltranspeptidase Drug:lidocaine Toxicity:lidocaine induced hepatitis. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|